Reuters logo
Teva to drop depression treatment after trial fails
2013年8月30日 / 下午4点44分 / 4 年前

Teva to drop depression treatment after trial fails

Aug 30 (Reuters) - Generic drugmaker Teva Pharmaceutical Industries Ltd said it will stop development of a depression treatment after a late-stage trial failed to show the drug was more effective than placebo.

The study was the third late-stage study that tested Nuvigil, or armodafinil, as an adjunct therapy in adults with major depression associated with bipolar I disorder.

While the first late-stage trial had positive results, the second trial failed.

Teva said it will not proceed with regulatory filings for the drug for treating bipolar-related depression. The drug is already approved to help adults who experience excessive sleepiness.

Teva said there will be no material impact to the company. The company’s US-listed shares were up slightly at $38.43 in afternoon trading.

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below